The Food and Drug Administration has accepted for review the supplemental New Drug Application for viloxazine extended-release for the treatment of attention-deficit hyperactivity disorder in adults. The application is supported by data from a multicenter, randomized, double-blind, placebo-controlled phase 3 trial (ClinicalTrials.gov Identifier: NCT04016779), which assessed the efficacy and safety of viloxazine in 374 adults…
While nearly one in three will experience points of remission of ADHD symptoms, most experience recurrence over time and few outgrow it
No increased risk seen for ADHD, ASD, small for gestational age with prenatal antipsychotics exposure
Azstarys consists of serdexmethylphenidate, a prodrug of dexmethylphenidate, co-formulated with immediate-release dexmethylphenidate.
Percentage changes were −51.3 and −17.4 percent for drug classes typically treating acute infections, chronic diseases
Lisdexamfetamine found to reduce symptoms of sluggish cognitive tempo in small group of adults with ADHD
The sNDA approval was based on data from a phase 3 Adult Laboratory Classroom study that assessed the efficacy and safety of Adhansia XR in adults diagnosed with ADHD.
This slideshow show drug information for Qelbree. Click here for the complete Qelbree monograph.
ADHD medications may moderate the association between externalizing symptoms and risk for suicidality in children
Qelbree is a selective norepinephrine reuptake inhibitor.
